BACKGROUND: Recent investigations have revealed multiple actions of vascular endothelial growth factor (VEGF) in the nervous system. The role of VEGF in the molecular background of mood disorders has also been proposed. In this study we were interested in investigating a possible association between VEGF levels and treatment response in patients with a current episode of major depression (MDE). METHODS: 34 patients with MDE were enrolled in our study. Depressive symptoms were monitored by the Montgomery-Åsberg Depression Rating Scale at baseline (V(1)) and after a 4-week treatment period (V(2)). Patients with less than a 50% improvement in MADRS total scores during this period were regarded as non-responders. RESULTS: Plasma VEGF levels did not change during the treatment period in either the total sample or in the responder and non-responder subsamples. There was a strong trend for higher baseline VEGF levels in the non-responder group than in the responder group (p=0.055) and this difference-as a weak trend-was still detectable at the end of the treatment period (p=0.097). Regression analysis revealed that the baseline VEGF level was a significant predictor for the endpoint MADRS score (p=0.02). LIMITATIONS: Sample size was relatively small; sample consists of both patients with MDD and bipolar disorder. CONCLUSIONS: Our preliminary results raise the possibility that baseline levels of peripheral VEGF may predict treatment response in patients with mood disorders. Considering the limitations of our study, further investigations should resolve whether VEGF is a useful biomarker for treatment response in depression in clinical practice.
BACKGROUND: Recent investigations have revealed multiple actions of vascular endothelial growth factor (VEGF) in the nervous system. The role of VEGF in the molecular background of mood disorders has also been proposed. In this study we were interested in investigating a possible association between VEGF levels and treatment response in patients with a current episode of major depression (MDE). METHODS: 34 patients with MDE were enrolled in our study. Depressive symptoms were monitored by the Montgomery-Åsberg Depression Rating Scale at baseline (V(1)) and after a 4-week treatment period (V(2)). Patients with less than a 50% improvement in MADRS total scores during this period were regarded as non-responders. RESULTS: Plasma VEGF levels did not change during the treatment period in either the total sample or in the responder and non-responder subsamples. There was a strong trend for higher baseline VEGF levels in the non-responder group than in the responder group (p=0.055) and this difference-as a weak trend-was still detectable at the end of the treatment period (p=0.097). Regression analysis revealed that the baseline VEGF level was a significant predictor for the endpoint MADRS score (p=0.02). LIMITATIONS: Sample size was relatively small; sample consists of both patients with MDD and bipolar disorder. CONCLUSIONS: Our preliminary results raise the possibility that baseline levels of peripheral VEGF may predict treatment response in patients with mood disorders. Considering the limitations of our study, further investigations should resolve whether VEGF is a useful biomarker for treatment response in depression in clinical practice.
Authors: Ajaykumar N Sharma; Bruno Fernando Borges da Costa e Silva; Jair C Soares; André F Carvalho; Joao Quevedo Journal: J Affect Disord Date: 2016-03-02 Impact factor: 4.839
Authors: Osvaldo P Almeida; Andrew H Ford; Leon Flicker; Graeme J Hankey; Bu B Yeap; Paula Clancy; Jonathan Golledge Journal: J Psychiatry Neurosci Date: 2014-05 Impact factor: 6.186
Authors: A Pillai; K R Howell; A O Ahmed; D Weinberg; K M Allen; J Bruggemann; R Lenroot; D Liu; C Galletly; C S Weickert; T W Weickert Journal: Mol Psychiatry Date: 2015-07-14 Impact factor: 15.992
Authors: T Xie; M G Stathopoulou; F de Andrés; G Siest; H Murray; M Martin; J Cobaleda; A Delgado; J Lamont; E Peñas-LIedó; A LLerena; S Visvikis-Siest Journal: Transl Psychiatry Date: 2017-03-07 Impact factor: 6.222
Authors: Andrew M Fukuda; Lauren E Hindley; Jee Won Diane Kang; Eric Tirrell; Audrey R Tyrka; Alfred Ayala; Linda L Carpenter Journal: Neuroreport Date: 2020-11-04 Impact factor: 1.703